Palvella Therapeutics: Funding, Investors & Team (Sep 2026)
Derived from the Finnish word for “to serve”, Palvella Therapeutics was founded with the single-minded goal of serving individuals suffering from serious rare genetic diseases with no approved treatments. By developing pathogenetically targeted therapies that address the root causes of these diseases, we believe we can dramatically enhance quality of life.
Palvella Therapeutics has raised $243M across 5 funding rounds on record, the most recent an undisclosed round of $200M announced in Feb 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Palvella Therapeutics Company Profile and Key Stats
Latest funding round on record: Feb 2026.
Palvella Therapeutics Funding Rounds
1 of 5 rounds was announced without a disclosed amount and is excluded from the total.
Palvella Therapeutics raised $37.7M in a Series D announced in Jan 2023.
1.8 years later, an undisclosed round of $2.6M was announced in Oct 2024.
2 months later, an undisclosed round was announced in Dec 2024 with no disclosed amount.
10 months later, an undisclosed round of $2.6M was announced in Oct 2025.
4 months later, an undisclosed round of $200M was announced in Feb 2026.
Palvella Therapeutics Founders and Leadership Team
Contact details for the Palvella Therapeutics team: 1 of 2 have an email address on file.
Start 14-day free trial →Palvella Therapeutics Funding Compared to Other Biotechnology Startups
Palvella Therapeutics' latest round of $200M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Palvella Therapeutics in Biotechnology and Wayne
Companies Similar to Palvella Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Palvella Therapeutics Funding FAQs
What does Palvella Therapeutics do?
Derived from the Finnish word for “to serve”, Palvella Therapeutics was founded with the single-minded goal of serving individuals suffering from serious rare genetic diseases with no approved treatments. By developing pathogenetically targeted therapies that address the root causes of these diseases, we believe we can dramatically enhance quality of life.
How much funding has Palvella Therapeutics raised?
Palvella Therapeutics has raised $243M across 5 rounds on record. The most recent is an undisclosed round of $200M announced in Feb 2026.
When did Palvella Therapeutics last raise funding?
Palvella Therapeutics' most recent funding round on record is an undisclosed round of $200M, announced in Feb 2026.
Who founded Palvella Therapeutics?
FundedIQ lists Wes Kaupinen (Founder), Wesley Kaupinen (Founder) at Palvella Therapeutics.
Where is Palvella Therapeutics headquartered?
Palvella Therapeutics is based in Wayne, Pennsylvania, United States.
How many employees does Palvella Therapeutics have?
Palvella Therapeutics is in the 1-10 employee band.
How does Palvella Therapeutics' funding compare to other Biotechnology startups?
Palvella Therapeutics' latest round of $200M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Palvella Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Palvella Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.